Veeda Clinical Research Limited

About Veeda Clinical Research

Veeda Clinical Research Limited (VCRL) is one of India's leading contract research organisations (CROs), headquartered in Ahmedabad, Gujarat. Incorporated in 2004 under CIN U73100GJ2004PLC044023, the company provides a comprehensive suite of drug development services including bioequivalence studies, Phase I–IV clinical trials, bioanalytical testing, and regulatory consulting to pharmaceutical, biotechnology, and medical device companies globally. Over two decades of operation, Veeda has established itself as a preferred outsourcing partner for generic pharmaceutical firms seeking USFDA, EMA, and other international regulatory approvals. Its state-of-the-art clinical pharmacology unit in Ahmedabad is equipped to conduct first-in-human and advanced clinical studies in a highly controlled environment. The company operates through a well-diversified global customer base spanning the United States, Europe, Japan, and South Asia. With revenues of approximately ₹408 crore in FY2024 and a workforce of around 923 employees, Veeda is among the top-tier CROs in the Indian subcontinent. Its business model is anchored in fee-for-service contracts, where clients pay for each clinical or analytical study conducted, providing relatively predictable revenue visibility. In a landmark strategic move, Veeda acquired Health Data Specialists Holding Limited (HEADS), an Ireland-based clinical research company specialising in oncology trials, in FY2024. This acquisition significantly expanded Veeda's global footprint and therapeutic capabilities, adding European clinical sites and oncology domain expertise. While the acquisition introduced one-time integration costs and elevated depreciation charges, it positions the company as a credible global CRO capable of conducting complex oncology studies. VCRL has received long-term credit ratings from CARE Ratings, reflecting the agency's assessment of its experienced management team, operational track record, and reputed customer relationships. The company operates from purpose-built facilities compliant with international Good Clinical Practice (GCP) guidelines, holding multiple regulatory accreditations that allow it to service clients across diverse jurisdictions. Looking ahead, Veeda is well-placed to capitalise on strong tailwinds in the global CRO market, which is driven by rising R&D outsourcing by Big Pharma and generic companies, India's cost-competitive advantage, a large patient pool, and accelerating generic drug approvals worldwide. The company's focus on expanding its oncology capabilities post-HEADS acquisition, growing its European presence, and deepening relationships with existing clients are central to its medium-term growth strategy.